WALTHAM, Mass., Aug 09, 2011 (BUSINESS WIRE) --
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving
science, announced today that it has priced its previously announced
offering of senior notes:
$1 billion aggregate principal amount of 2.250% senior notes due 2016
at an issue price of 99.826% of the principal amount, and
$1.1 billion aggregate principal amount of 3.600% senior notes due
2021 at an issue price of 99.809% of the principal amount.
The issuance of the notes is expected to close on August 16, 2011. The
notes will pay interest on a semi-annual basis.
The company plans to use the proceeds of the offering to fund, in part,
the company's acquisition of Phadia. The aggregate purchase price of
this transaction is estimated to be EUR 2.47 billion (approximately $3.5
billion). The Phadia acquisition was announced by the company on May 19,
The joint book-running managers for the offering are Barclays Capital
Inc., Merrill Lynch, Pierce, Fenner & Smith Incorporated, J.P. Morgan
Securities LLC, Deutsche Bank Securities Inc., RBS Securities Inc., and
Goldman, Sachs & Co.
Thermo Fisher has filed a registration statement on Form S-3 (including
a prospectus) with the Securities and Exchange Commission (the "SEC")
for this offering. Prospective investors should read the prospectus
forming a part of that registration statement and the prospectus
supplement related to the offering and the other documents that the
company has filed with the SEC for more complete information about the
company and this offering. These documents are available at no charge by
visiting EDGAR on the SEC website at www.sec.gov.
Alternatively, these documents will be made available upon request by
the company or by any active joint book-running manager for the
offering. Interested parties may obtain a prospectus or the related
preliminary prospectus supplement from Barclays Capital Inc. by
directing a request to Barclays Capital Inc., c/o Broadridge Integrated
Prospectus Distribution, 1155 Long Island Avenue, New York, NY 11717, or
by calling 1-888-603-5847; from Merrill Lynch, Pierce, Fenner & Smith
Incorporated by directing a request to 1-800-294-1322 or from J.P.
Morgan Securities LLC by directing a request to J.P. Morgan Securities
LLC, 383 Madison Avenue, New York, NY 10179, Attn: High Grade Syndicate
Desk - 3rd Floor or by calling 212-834-4533.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy the notes, nor shall there be any offer,
solicitation or sale of the notes in any jurisdiction in which such
offer, solicitation or sale would be unlawful prior to the registration
or qualification under the securities laws of any such jurisdiction.
SOURCE: Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc.
Media Contact Information:
Ron O'Brien, 781-622-1242
Investor Contact Information:
Ken Apicerno, 781-622-1294